Status:
UNKNOWN
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Acute Ischemic Stroke
Thrombocytopenia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplate...
Detailed Description
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytop...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- Acute ischemic stroke or transient ischemic attack with onset \< 7 days
- The last blood routine test before enrollment indicates platelet count \< 100 x 10\^9 and \> 30 x 10\^9
Exclusion
- Chronic renal dysfunction (GFR \< 30ml/min) or severe hepatic injury
- Indications for anticoagulation therapy, e.g. atrial fibrillation
- Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past
- Have or plan to receive CEA or CAS in the following 3 months
- Life expectancy less than 1 year
- Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding
- Pregnant or lactating women
- Individuals identified by researchers as unsuitable for participation in the study due to other reasons.
Key Trial Info
Start Date :
September 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06053021
Start Date
September 15 2023
End Date
January 1 2026
Last Update
October 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China